There has been a delay to the European Medicines Agency’s review process for Leqembi (lecanemab).
Swedish developer BioArctic (Nasdaq Stockholm: BIOA B) and partner Eisai (TYO: 4523), a Japanese drugmaker, have announced that an oral session of the agency’s scientific review committee did not go ahead as planned on 19 March.
The delay was not as a result of anything to do with the candidate or the submission, but was due to “procedural reasons,” BioArctic said in a statement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze